Fernando Tatsch

607 total citations
42 papers, 412 citations indexed

About

Fernando Tatsch is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Fernando Tatsch has authored 42 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Hepatology, 28 papers in Epidemiology and 9 papers in Infectious Diseases. Recurrent topics in Fernando Tatsch's work include Hepatitis C virus research (36 papers), Liver Disease Diagnosis and Treatment (19 papers) and Hepatitis B Virus Studies (18 papers). Fernando Tatsch is often cited by papers focused on Hepatitis C virus research (36 papers), Liver Disease Diagnosis and Treatment (19 papers) and Hepatitis B Virus Studies (18 papers). Fernando Tatsch collaborates with scholars based in United States, Switzerland and Brazil. Fernando Tatsch's co-authors include Jordan J. Feld, Ira M. Jacobson, Fred Poordad, Mark Sulkowski, Jean–Michel Pawlotsky, Patrick Marcellin, Peter Ferenci, Hugo Cheinquer, Donald M. Jensen and Raymundo Paraná and has published in prestigious journals such as Blood, Gastroenterology and PLoS ONE.

In The Last Decade

Fernando Tatsch

39 papers receiving 395 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fernando Tatsch United States	11	336	316	62	27	18	42	412
Kerstin Stein Germany	7	363 1.1×	410 1.3×	97 1.6×	23 0.9×	20 1.1×	19	502
Feng Su United States	8	337 1.0×	322 1.0×	44 0.7×	12 0.4×	26 1.4×	13	428
S. Gordon United States	9	213 0.6×	221 0.7×	59 1.0×	16 0.6×	10 0.6×	14	295
Dragan Delić Serbia	11	257 0.8×	274 0.9×	39 0.6×	10 0.4×	13 0.7×	46	351
Wen Ouyang United States	6	154 0.5×	141 0.4×	64 1.0×	11 0.4×	10 0.6×	11	220
Solange Heller Mexico	7	168 0.5×	174 0.6×	7 0.1×	51 1.9×	11 0.6×	9	252
T.J. Layden United States	4	419 1.2×	434 1.4×	40 0.6×	10 0.4×	19 1.1×	7	503
Elena Younossi United States	6	188 0.6×	365 1.2×	44 0.7×	4 0.1×	25 1.4×	14	420
Rachele Rapetti Italy	8	212 0.6×	237 0.8×	26 0.4×	18 0.7×	23 1.3×	15	306

Countries citing papers authored by Fernando Tatsch

Since Specialization

Citations

This map shows the geographic impact of Fernando Tatsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando Tatsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando Tatsch more than expected).

Fields of papers citing papers by Fernando Tatsch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fernando Tatsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando Tatsch. The network helps show where Fernando Tatsch may publish in the future.

Co-authorship network of co-authors of Fernando Tatsch

This figure shows the co-authorship network connecting the top 25 collaborators of Fernando Tatsch. A scholar is included among the top collaborators of Fernando Tatsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fernando Tatsch. Fernando Tatsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Forns, Xavier, Jordan J. Feld, Douglas E. Dylla, et al.. (2021). Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts. Advances in Therapy. 38(6). 3409–3426. 7 indexed citations

Dore, Gregory J., Jordan J. Feld, Marianne Martinello, et al.. (2019). Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. Journal of Hepatology. 72(3). 431–440. 26 indexed citations

Mangia, Alessandra, Victor de Lédinghen, François Bailly, et al.. (2016). IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. SpringerPlus. 5(1). 1990–1990. 13 indexed citations

Shiffman, Mitchell L., Hugo Cheinquer, Christoph P. Berg, et al.. (2014). Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial. Hepatology International. 8(4). 517–526. 4 indexed citations

Marcellin, Patrick, Antonio Craxı̀, Carlos Eduardo Brandão‐Mello, et al.. (2013). Predicting Early and Sustained Virological Responses in Prior Nonresponders to Pegylated Interferon alpha-2b Plus Ribavirin Retreated With Peginterferon alpha-2a Plus Ribavirin and the Benefit-Risk Ratio of Retreatment. Journal of Clinical Gastroenterology. 47(9). 786–793.

Ferenci, Péter, Kimberly L. Beavers, Manuela Curescu, et al.. (2013). Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients. Hepatology International. 8(1). 83–93. 6 indexed citations

Berg, Thomas, Stefan Zeuzem, Christoph P. Berg, et al.. (2013). 792 48 WEEKS OF PEGINTERFERON alfa-2a/RIBAVIRIN IMPROVES SVR24 AND DECREASES RELAPSE ACROSS HCV GENOTYPE 2/3 PATIENT SUBGROUPS NOT ACHIEVING A RAPID VIROLOGICAL RESPONSE: N-CORE STUDY. Journal of Hepatology. 58. S323–S323. 2 indexed citations

Harrison, Stephen A., Mitchell L. Shiffman, И. Г. Бакулин, et al.. (2012). Intensified Peginterferon α-2a Dosing Increases Sustained Virologic Response Rates in Heavy, High Viral Load Hepatitis C Genotype 1 Patients With High Low-density Lipoprotein. Journal of Clinical Gastroenterology. 47(3). 271–279. 3 indexed citations

Marcellin, Patrick, Hugo Cheinquer, Manuela Curescu, et al.. (2012). High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology. 56(6). 2039–2050. 79 indexed citations

10.

Badiger, Rekha, Jane A. Mitchell, Stefan Foser, et al.. (2012). Effect of Different Interferonα2 Preparations on IP10 and ET-1 Release from Human Lung Cells. PLoS ONE. 7(10). e46779–e46779. 11 indexed citations

11.

Marcellin, Patrick, Stuart K. Roberts, K. Rajender Reddy, et al.. (2012). Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opinion on Drug Safety. 11(6). 901–909. 3 indexed citations

12.

Marcellin, Patrick, Nancy Reau, Peter Ferenci, et al.. (2012). Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. Journal of Hepatology. 56(6). 1276–1282. 16 indexed citations

13.

Foster, Graham R., et al.. (2012). 1110 BASELINE PREDICTORS FOR SAFETY-RELATED DOSE REDUCTIONS OR TREATMENT DISCONTINUATIONS AMONG PEGINTERFERON ALFA-2A (40KD)/RIBAVIRIN-TREATED PATIENTS AND THEIR IMPACT ON EARLY TREATMENT RESPONSES: GUARD-C INTERIM ANALYSIS. Journal of Hepatology. 56. S437–S438. 1 indexed citations

14.

Ammirati, Adriano Luiz, Renato Watanabe, Sérgio Antônio Draibe, et al.. (2010). Variação dos níveis de hemoglobina de pacientes em hemodiálise tratados com eritropoetina: uma experiência brasileira. Revista da Associação Médica Brasileira. 56(2). 209–213. 7 indexed citations

15.

Quarantini, Lucas C., María Isabel Schinoni, Aline S. Sampaio, et al.. (2006). Effect of Amantadine on Depressive Symptoms in Chronic Hepatitis C Patients Treated with Pegylated Interferon. Clinical Neuropharmacology. 29(3). 138–143. 35 indexed citations

16.

Tatsch, Fernando, et al.. (2006). Pharmacoeconomics applied to chronic hepatitis C. The Brazilian Journal of Infectious Diseases. 10(1). 51–54. 2 indexed citations

17.

Tavares‐Neto, José, et al.. (2006). Serological markers of hepatitis A, B and C viruses in rural communities of the semiarid Brazilian Northeast. The Brazilian Journal of Infectious Diseases. 10(5). 317–21. 13 indexed citations

18.

Cheinquer, Hugo, Ana de Lourdes Candolo Martinelli, Hoel Sette, et al.. (2006). Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy. The Brazilian Journal of Infectious Diseases. 10(1). 11–16. 22 indexed citations

19.

Takahama, Ademar, et al.. (2005). Hepatitis C: incidence and knowledge among Brazilian dentists.. PubMed. 22(3). 184–7. 18 indexed citations

20.

Brandão, Carlos Eduardo, Mário Guimarães Pessôa, Marco Olivera‐Martinez, et al.. (2002). Prospective evaluation of early virological response associated with peginterferon alfa-2a (40KD) (Pegasys (R)) and ribavirin from a phase IV, randomized study examining the effects of treatment duration-in hepatitis C patients infected with genotype 1.. Hepatology. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact